

NCT ID	NCT03638297
Title	PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
Phase	Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	PD-1 antibody + cox inhibitor
Tags	MSI-H/ MMRd
NCT ID	NCT05759728
Title	A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2023-03-08
Location	Australia
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05768503
Title	Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase	Phase 3
Date Added	2023-03-14
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Control Rx, Experimental drug
Tags	MSS/ MMRp
NCT ID	NCT05770102
Title	DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Phase	Phase 2, Phase 3
Date Added	2023-03-15
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab
Tags	MSI-H/ MMRd
NCT ID	NCT05771181
Title	Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2023-03-16

Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, Tislelizumab, Vitamin E
Tags	MSS/ MMRp
NCT ID	NCT05976906
Title	Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Phase	Phase 1
Date Added	2023-08-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05438342
Title	An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
Phase	Not Applicable
Date Added	2022-06-29
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Chemotherapy?checkpoint immunotherapy, targeted therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05464030
Title	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase	Phase 1
Date Added	2022-07-19
Location	California, United States Rhode Island, United States Texas, United States Canada Japan South Korea Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	M9140
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05479812
Title	Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-07-29

Location	Arizona, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Indiana, United States
	Minnesota, United States
	New Jersey, United States
	New York, United States
	Oregon, United States
	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Pembrolizumab, WTX-124
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT05482516
Title	Evaluating Novel Therapies in ctDNA Positive GI Cancers
Phase	Phase 3
Date Added	2022-08-01
Location	District of Columbia, United States
	New Jersey, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, Avastin, Tecentriq
Tags	MSI-H/ MMRd, MSS/ MMRp